MARKET

HOOK

HOOK

Hookipa Pharma
NASDAQ
1.210
+0.010
+0.83%
Opening 12:50 03/28 EDT
OPEN
1.200
PREV CLOSE
1.200
HIGH
1.240
LOW
1.170
VOLUME
26.62K
TURNOVER
--
52 WEEK HIGH
10.50
52 WEEK LOW
1.110
MARKET CAP
14.59M
P/E (TTM)
-0.3488
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HOOK last week (0317-0321)?
Weekly Report · 4d ago
Weekly Report: what happened at HOOK last week (0310-0314)?
Weekly Report · 03/17 09:25
Tracking Baker Brothers Portfolio - Q4 2024 Update
Seeking Alpha · 03/13 03:56
Weekly Report: what happened at HOOK last week (0303-0307)?
Weekly Report · 03/10 09:25
Hookipa Pharma (HOOK) Receives a Hold from RBC Capital
TipRanks · 03/04 01:46
Weekly Report: what happened at HOOK last week (0224-0228)?
Weekly Report · 03/03 09:25
HOOKIPA PHARMA INC. (Exact name of registrant as specified in its charter) Annual Report (Form 10-K) for the fiscal year ended December 31, 2024
Press release · 03/01 00:27
Weekly Report: what happened at HOOK last week (0217-0221)?
Weekly Report · 02/24 09:25
More
About HOOK
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.

Webull offers Hookipa Pharma Inc stock information, including NASDAQ: HOOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HOOK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HOOK stock methods without spending real money on the virtual paper trading platform.